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Wei Chen4, Dawen Sui5, Roland L. Bassett5, Li-E Wang6, Qingyi Wei7, Christopher I. Amos8,9 and
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Recent investigation has identiﬁed association of IL-12p40 blood levels with melanoma recurrence and patient
survival. No studies have investigated associations of single-nucleotide polymorphisms (SNPs) with melanoma
patient IL-12p40 blood levels or their potential contributions to melanoma susceptibility or patient outcome. In
the current study, 818,237 SNPs were available for 1,804 melanoma cases and 1,026 controls. IL-12p40 blood levels
were assessed among 573 cases (discovery), 249 cases (case validation), and 299 controls (control validation).
SNPs were evaluated for association with log[IL-12p40] levels in the discovery data set and replicated in two
validation data sets, and signiﬁcant SNPs were assessed for association with melanoma susceptibility and patient
outcomes. The most signiﬁcant SNP associated with log[IL-12p40] was in the IL-12B gene region (rs6897260,
combined P= 9.26× 10− 38); this single variant explained 13.1% of variability in log[IL-12p40]. The most signiﬁcant
SNP in EBF1 was rs6895454 (combined P= 2.24× 10− 9). A marker in IL12B was associated with melanoma
susceptibility (rs3213119, multivariate P= 0.0499; OR= 1.50, 95% CI 1.00–2.24), whereas a marker in EBF1 was
associated with melanoma-speciﬁc survival in advanced-stage patients (rs10515789, multivariate P= 0.02;
HR= 1.93, 95% CI 1.11–3.35). Both EBF1 and IL12B strongly regulate IL-12p40 blood levels, and IL-12p40
polymorphisms may contribute to melanoma susceptibility and inﬂuence patient outcome.
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INTRODUCTION
IL-12 and IL-23 share a common subunit, interleukin (IL)-
12p40. IL-12p40 associates with IL-12p35 and IL-23p19 to
form IL-12 (IL-12p70) and IL-23, respectively; IL-12p40 can
also exist in a monomeric form and have an independent role
in immunity (Cooper and Khader, 2007). The heterodimeric
cytokine IL-12 has a role in protective resistance and adaptive
immunity in response to intracellular pathogens (Trinchieri,
2003), as well as having antitumor activity (Fallarino et al.,
1996; Quaglino et al., 2002). In contrast, IL-23 contributes to
autoimmune inﬂammation (Langrish et al., 2004) and stimu-
lates tumor growth through the induction of tumor-promoting
microenvironments (Langowski et al., 2006). The IL-12p40
subunit also appears to be capable of combining with a
variety of additional proteins to function as a pleiotropic
adaptor (Abdi et al., 2014). Interestingly, dendritic cells
producing IL-12p70 have been used to immunize melanoma
patients, suggesting that IL-12p70 has therapeutic potential
(Carreno et al., 2013); the contribution of the IL-12p40 subunit
to such a treatment strategy remains undeﬁned. Cytokines
such as IL-12 and IL-23 mediate host responses to tumors;
blood levels of these cytokines might therefore serve as
biomarkers for the early diagnosis or prognosis of cancer, and
if linked to disease incidence or progression could suggest
new treatment strategies. Standard assays test the IL-12p40
subunit, representing the sum total of the free monomer as
well as heterodimer combinations including IL-12 and IL-23.
Intriguingly, measured levels of IL-12p35 and IL-23α in blood
ORIGINAL ARTICLE
1Department of Surgical Oncology, The University of Texas MD Anderson
Cancer Center, Houston, Texas, USA; 2Department of Surgery, Virginia Piper
Cancer Institute, Minneapolis, Minnesota, USA; 3Division of Rheumatology and
Clinical Immunogenetics, The University of Texas Health Science Center at
Houston, Houston, Texas, USA; 4Department of Genetics, The University of
Texas MD Anderson Cancer Center, Houston, Texas, USA; 5Department of
Biostatistics, The University of Texas MD Anderson Cancer Center, Houston,
Texas, USA; 6Department of Epidemiology, The University of Texas MD
Anderson Cancer Center, Houston, Texas, USA; 7Duke Cancer Institute, Duke
University Medical Center and Department of Medicine, Duke University
School of Medicine, Durham, North Carolina, USA and 8Geisel College of
Medicine, Community and Family Medicine, Dartmouth College, Lebanon,
New Hampshire, USA
Correspondence: Shenying Fang or Jeffrey E. Lee, Department of Surgical
Oncology, The University of Texas M. D. Anderson Cancer Center, Unit 1484,
1400 Pressler Street, FCT17.6000, Houston, Texas 77030-4009, USA.
E-mail: sfang@mdanderson.org or jelee@mdanderson.org
9These authors contributed equally to this work.
Received 5 September 2014; revised 19 March 2015; accepted 28 March
2015; accepted article preview online 7 April 2015; published online 14 May
2015
2266 Journal of Investigative Dermatology (2015), Volume 135 © 2015 The Society for Investigative Dermatology
are usually far too low to account for the corresponding levels
of IL-12p40, which are typically much higher.
IL-12p40 is coded by the IL12B gene on 5q31.1-q33.1.
Other genes might also inﬂuence the blood level of IL-12p40.
Defects in IL12B confer Mendelian susceptibility for myco-
bacterial disease (Altare et al., 1998; Casanova, 2001), and
SNPs in IL12B are signiﬁcantly associated with both psoriasis
(Cargill et al., 2007; Strange et al., 2010) and asthma (Randolph
et al., 2004). No former studies have directly investigated
common genetic determinants of IL-12p40 levels in blood,
especially among melanoma cases and controls. In a separate
investigation, we recently demonstrated that an elevated plasma
level of IL-12p40 was associated with disease recurrence and
poor survival in melanoma patients (Fang et al., 2014). Therefore,
we hypothesized that evaluation of genetic determinants
of IL-12p40 blood levels among melanoma patients could
provide new insights into the etiology and progression of
melanoma.
RESULTS
Overall, 2.65 million genotyped or imputed SNPs were
available for 1,804 melanoma cases and 1,026 controls.
Peripheral blood samples were obtained from 573 cases
(discovery data set), 249 cases (validation dataset), and 299
controls (validation dataset) (Supplementary Figure S1 online).
As previously described (Fang et al., 2014), the distribution of
raw IL-12p40 levels in the discovery and case validation data
sets was skewed but was symmetric following log transforma-
tion. Similar distribution was observed for the control data set
(Supplementary Figure S2 online). Therefore, log[IL-12p40] was
used in the GWAS analysis (Supplementary Figure S3 online).
As previously reported, after accounting for the batch effect,
IL-12p40 levels were close between melanoma patients and
controls (Fang et al., 2014). We previously observed no
correlation between blood storage time and plasma IL-12p40
levels over a 2-year period (retesting the same blood samples
from the same patient using the same assay kit) (Fang et al.,
2014). In the present study again we assessed for correlation
between storage time and raw or log-transformed IL-12p40 for
all observations (up to 8 years’ storage time) and found no
signiﬁcant correlation between IL-12p40 levels and storage
time in any of the three data sets (Supplementary Table S1
online; Pearson’s correlation coefﬁcients 0.0625 [discovery;
P=0.1354], 0.0114 [case validation; P=0.8576], and 0.1113
[control validation; P=0.0545]). We therefore made no
adjustment for storage time in our analyses. The association of
melanoma patient demographic and clinical covariates with log
[IL-12p40] for this population has been previously reported
(Fang et al., 2014).
High-density genotype data and plasma IL-12p40 levels
were available for 573 melanoma cases in the discovery data
set. The Q-Q plot for the genotyped and imputed SNPs in
the discovery melanoma cases is shown in Supplementary
Figure S4 online. The inﬂation factor lambda (λ) calculated for
the genomic control analysis in the initial discovery cohort
was 1.022, very close to 1.0. The plot indicates little evidence
of population substructure but suggests strong associations
with IL-12p40. Further inclusion of the ﬁrst three principal
components as covariates slightly increased λ to 1.029.
Association results across the whole-genome are shown in
Figure 1 and SNPs having P-values less than 10− 5 across the
entire genome are listed in Supplementary Table S2 online.
The most signiﬁcant region comprised 346 kb on chromo-
some 5q and included four genes: EBF1, FLJ31951, UBLCP1,
and IL12B (Supplementary Figure S5 and S6 online). The
top signiﬁcant observed SNP in this region was rs6897260
(minor allele frequency= 0.315; P= 1.49× 10− 19 with log
[IL-12p40]) (Table 1 and Supplementary Table S2 online). The
most signiﬁcant imputed SNP, rs4921484, had a P-value of
5.01× 10−19 and was in high linkage disequilibrium (LD)
with rs6897260 (r2= 0.991, Supplementary Figure S5 online).
Those genotyped SNPs in moderate-to-high LD with the most
signiﬁcant SNP were also found to be signiﬁcantly associated
with log[IL-12p40]) (r2= 0.874 with the second most sig-
niﬁcant genotyped SNP, rs10045431; P= 1.29×10− 16;
Supplementary Figure S5 online). Two missense SNPs
genotyped in the IL12B gene, rs3213119 and rs3213096,
had minor allele frequencies of 0.0296 and 0.0077, and
P-values of 5.26×10−14 and 0.136 with log[IL-12p40],
respectively. The minor allele “A” of rs3213119, coding for
a valine to phenylalanine mutation, was signiﬁcantly asso-
ciated with lower IL-12p40 levels. However, the minor allele
“T” of rs3213096, coding for a valine to isoleucine mutation,
was not signiﬁcantly associated with IL-12p40 levels. The top
signiﬁcant imputed variant in EBF1 was rs6895454
(P=7.65× 10−11), and the top signiﬁcant observed variant
in this gene region was rs12054738 (P= 2.57×10−10). These
two SNPs were in moderate LD, with r2= 0.645
(Supplementary Figure S6 online). After adjustment for the
most signiﬁcant SNP rs6897260, no other SNPs remained
signiﬁcant at 5× 10− 8; two additional SNPs remained
borderline signiﬁcant, rs3213119 (missense SNP) and
rs3213120. These two SNPs are located in IL12B (both
P-values equal to 6.57× 10− 8).
19
18
17
16
15
14
13
12
11
10
9
–
lo
g 1
0(p
)
8
7
6
5
4
3
2
1
1 2 3 4 5 6 7
Chromosome
8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Figure 1. Manhattan plot for SNPs with log10-transformed IL-12p40. The
upper red line represents genome-wide signiﬁcance level 5×10E-8 and lower
dash line is the signiﬁcance level (10E-5) applied in the analysis to choose
SNPs for further replication.
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We examined the signiﬁcant region (158400–158800 kb)
on chromosome 5 in HapMap 2 and found 15 haplotype
blocks based on LD between pair-wise SNPs. Our signiﬁcant
SNPs in Supplementary Table S2 online, were located in eight
blocks. Because we totally identiﬁed 92 SNPs that were
related to log[IL-12p40] with Po10−5, in order to reduce
redundant SNPs associated with log[IL-12p40] due to LD
between SNPs, and also reduce the multiple testing problem,
we chose the most signiﬁcant SNP from each block region
and then validated the observed association between these
SNP markers and log[IL-12p40] in an additional 249
melanoma cases (validation case set) and 299 controls
(validation control set). The LD matrix between ten SNPs
(eight block-representative SNPs plus two missense mutation
SNPs) in each sample is listed in Supplementary Table S3
online. The most signiﬁcant SNP, rs6897260, was strongly
associated with log[IL-12p40] among the replication case
group (P=3.64× 10−10), control group (P= 4.13× 10− 12),
and in the combined group in meta-analysis (P=9.26×
10−38). The “A” allele of this variant contributes to decreased
log[IL-12p40] level (Table 1, Supplementary Table S2 online).
Three of the ten SNPs remained signiﬁcant (Po0.01) in the
model after further multipoint stepwise regression (Supple-
mentary Table S4 online). Two of these three SNPs were
within the IL12B region and one within the EBF1 region, and
the top signiﬁcant variant rs6897260 in IL12B was in low LD
with the top signiﬁcant variant rs10515789 in EBF1
(r2=0.0375 in the discovery data set, Supplementary Table
S3 online), indicating that the variants in the EBF1 region had
an independent effect on the IL-12p40 level. These three
SNPs together accounted for 18.7% of the variation in the
IL-12p40 level in the discovery group, whereas the most
signiﬁcant SNP rs6897260 alone explained 13.1% of
variability in the IL-12p40 level. These three variants were
still signiﬁcant after taking into account sex and age in the
ﬁnal model (Po0.01).
The above single variant test has inadequate statistical
power to obtain the majority of true effects in the GWAS
of a few thousand individuals because some genuine
susceptibility loci do not achieve genome-wide signiﬁcance
level but may nonetheless be signiﬁcant after combining
results from different groups. Gene-based association testing
can be used to improve the power of a GWAS. In gene-based
analysis, the chi-squared statistics of each SNP in a gene are
combined while also adjusting for LD structure and gene size,
and a permutation test is run to obtain the empirical gene-
based P-value (Liu et al., 2010). Therefore, to further evaluate
gene regions associated with IL-12p40 blood levels, we
performed a gene-based test. Results from this test demon-
strated strong evidence associating markers in the IL12B and
UBLCP1 genes with log[IL-12p40] (both P-values o10− 6);
markers in the FLJ31951 (P= 1.30×10−5) and EBF1
(P=5.99× 10−4) genes did not achieve statistical signiﬁcance
for log[IL-12p40] at the critical value of 2.8× 10−6
(0.05/17,787) in the discovery data set. Application of the
gene-based test also conﬁrmed the association of the IL12B
gene region with IL-12p40 in both validation groups
(Supplementary Table S5 online).
Eight block-representative SNPs and two missense mutation
SNPs on chromosome 5 were further evaluated for their
association with melanoma susceptibility among 1804 cases
and 1026 controls and with overall survival, melanoma-
speciﬁc survival, and relapse-free survival among 1804
melanoma patients (1412 with stage I/II and 388 with stage
III/IV). A single marker in IL12B was related to melanoma
susceptibility (rs3213119, P= 0.002; less than a Bonferroni-
adjusted P-value of 0.005 in the univariate analysis;
P= 0.0499, OR= 1.50, 95% CI 1.00–2.24 when adjusting
for gender, age, eye color, skin color, hair color, and sunburn
in the multivariate analysis), whereas a single marker in EBF1
was associated with melanoma-speciﬁc survival among
melanoma patients with stage III or IV disease (rs10515789,
Table 1. Signiﬁcance of eight block-representative SNPs and two missense mutation SNPs on chromosome 5 in
genome-wide analysis of log[IL-12p40]
SNP
Minor/
Major MAF Position
P-value
IL-12, Cases
(Stage 1,
n=573)
P-value
IL-12, Cases
(Stage 2,
n= 249)
P-value IL-12,
Controls
(Stage 2,
n= 299)
P-value,
overall
Regression
Coefﬁcient
(β) minor
allele
Standard
error of β
Imputed
or
genotyped Gene
rs10515789 G/T 0.0591 158438993 2.51×10−10 9.81× 10−2 1.15× 10−3 8.90× 10−11 −0.369 0.052 Imputed EBF1
rs6895454 T/C 0.0676 158455745 7.65×10−11 1.54× 10−1 1.54× 10−2 2.24× 10−9 −0.339 0.050 Imputed EBF1
rs10515775 T/C 0.1171 158523032 1.10× 10−6 2.73× 10−1 5.53× 10−1 1.51× 10−4 −0.161 0.037 Genotyped FLJ3195
rs919766 C/A 0.1108 158680142 2.50×10−14 7.03× 10−4 6.70× 10−6 3.35× 10−19 −0.339 0.035 Imputed IL12B
rs3181219 A/G 0.1093 158684717 6.11×10−15 7.07× 10−4 6.66× 10−6 1.30× 10−19 −0.344 0.035 Imputed IL12B
rs10052709 G/C 0.1401 158693055 9.14×10−14 3.77× 10−5 1.49× 10−4 7.21× 10−19 −0.310 0.033 Imputed IL12B
rs4921484 T/C 0.3133 158702331 5.01×10−19 4.18× 10−10 5.54× 10−12 4.00× 10−37 −0.316 0.024 Imputed IL12B
rs6897260 A/G 0.3145 158735664 1.49×10−19 3.64× 10−10 4.13× 10−12 9.26× 10−38 −0.316 0.023 Genotyped IL12B
rs3213119 A/C 0.0296 158676366 5.26×10−14 1.54× 10−4 3.35× 10−4 7.93× 10−18 −0.632 0.068 Genotyped IL12B
rs3213096 T/C 0.0077 158682907 1.36× 10−1 4.86× 10−1 5.63× 10−1 1.10× 10−1 0.245 0.193 Imputed IL12B
Abbreviations: MAF, minor allele frequency; SNP, single nucleotide polymorphism.
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P=0.0045, less than nominal signiﬁcance level in the
univariate analysis; P= 0.0206, HR= 1.93, 95% CI 1.11–
3.35 when adjusting for gender, age, and tumor thickness in
the multivariate analysis) (Supplementary Table S6 and S7
online, Table 2).
DISCUSSION
Melanoma tumors are relatively immunogenic, and immu-
notherapy has been shown to be increasingly effective against
advanced melanoma (Nagai et al., 2010; Hamid et al., 2013;
Riley, 2013; Wolchok et al., 2013). Immunotherapeutic
approaches have included checkpoint blockade (anti-
CTLA4, anti-PD1, anti-PDL1), IFN-α, IL-2, vaccines, and
adoptive immunotherapy. Although recent results with check-
point blockade in particular are promising, the efﬁcacy and
toxicity of such therapies vary across patients. Characteri-
zation of immune and inﬂammatory mechanisms has
therefore remained an important goal in melanoma research.
A role for IL-12p40 in cancer-related inﬂammation and tumor
growth has been identiﬁed (Trinchieri, 2003); we therefore
sought to investigate genetic variants that regulate the
expression of IL-12p40 and assess the role of these genetic
polymorphisms in melanoma prognosis.
In our prior study, a direct association was identiﬁed and
validated between elevated IL-12p40 blood levels and an
elevated risk of melanoma recurrence, as well as poorer
melanoma-speciﬁc and overall survival, especially in
early-stage patients (Fang et al., 2014). In the current study,
two-stage GWAS identiﬁed strong associations between
IL-12p40-related polymorphisms and plasma IL-12p40
levels in both melanoma patients and non-cancer control
individuals. Our current results also provide preliminary
evidence for associations between IL-12p40-related poly-
morphisms and risk for melanoma susceptibility and death
from melanoma. Thus, the current study extends our prior
investigation by identifying a strong component of genetic
control of IL-12p40 expression, including in melanoma
patients, and suggests that validation and additional investi-
gation of the potential role of IL-12p40-related genes in
melanoma tumorigenesis, disease progression, and patient
outcomes is warranted.
We used an assay that recognizes IL-12p40 both in
heterodimers such as IL-12 or IL-23 and as a free subunit.
Postulating that IL-12p40-related genetic polymorphisms may
inﬂuence melanoma patient prognosis through altered IL-12p40
expression is reasonable, but such a hypothesis remains to be
directly investigated. Interestingly, EBF1 is adjacent to IL12B on
chromosome 5. EBF1 is a transcriptional activator that regulates
transcription of IL12B, which codes for IL-12p40 in blood; it is
therefore reasonable to hypothesize that EBF1 polymorphisms
could help regulate IL-12p40 blood levels.
Our study has some limitations. Although associations bet-
ween IL-12p40-related genetic polymorphisms and IL-12p40
blood levels are strong and validated, and our prior investiga-
tion identiﬁed and validated associations between IL-12p40
blood levels and melanoma outcomes, the ﬁndings in the
current investigation linking gene variants in IL12B and EBF1
with melanoma risk and patient outcomes must be considered
preliminary until they are independently conﬁrmed. Further-
more, blood samples in this investigation were obtained,
stored, and batch processed over as long as 8 years, resulting in
the potential for bias if IL-12p40 blood levels change with
prolonged storage time. In our previous investigation, we
reported that IL-12p40 levels did not appear to change when
the same blood samples from the same patient were retested
using the same assay kit after a 2-year interval (Fang et al.,
2014). In the current study, we observed the relationship
between storage time and IL-12p40 levels in our three data
sets; we found no signiﬁcant correlation over storage times as
long as 8 years. Although we cannot completely exclude the
possible inﬂuence of storage time on some of our ﬁndings,
the strength and robustness of the genetic associations
with IL-12p40 blood levels were unlikely to be signiﬁcantly
inﬂuenced by a small sample storage effect, and the analysis of
association between gene variants and patient outcomes was
performed independent of IL-12p40 blood levels.
In our analysis, the most signiﬁcant SNP in IL12B
rs6897260 accounted for 13.1% of variation in IL-12p40
levels, and the top three SNPs together accounted for 18.7%
of the variation. This indicates strong genetic control of
IL-12p40 blood levels in humans but also leaves open the
likelihood of major inﬂuences from non-genetic factors. SNPs
in EBF1 and FLJ31951 explained only a small proportion of
trait variance (far less than 10%), and therefore we did not
have adequate power to detect their effects. This may explain
why only the IL12B association was successfully replicated in
the two validation groups. For the missense SNP rs3213096,
assuming the frequencies of the trait increasing allele and the
marker allele are both 0.0077 and the same values for other
parameters as above, a signiﬁcance level of 5.0× 10− 8 will
have a power of 93.4% to detect the association in the
discovery data set. Therefore, a nonsigniﬁcant result for
rs3213096 with the IL12p40 level could be because this SNP
accounts for only a small proportion of trait variance (far less
than 10%), or alternatively because this SNP does not
contribute to regulation of IL-12p40 levels.
If common SNPs in IL12B are associated with IL-12p40
levels, and IL-12 contributes to the etiology of psoriasis, then
IL-12p40-related SNPs should be identiﬁed in GWAS studies
of susceptibility to psoriasis or vice versa. Cargill et al.
performed GWAS of psoriasis risk (Cargill et al., 2007). In the
IL12B gene regions, the most signiﬁcant 2 SNPs were
rs3212227 (P= 7.85×10−10) and rs6887695 (P= 4.08×
10−8) in the combined data set. However, the two missense
SNPs rs3213119 and rs3213096 were not signiﬁcantly
associated with psoriasis risk in their discovery data set
(P=0.68 and P=0.122, respectively). In our GWAS of
IL-12p40 in combined the data set, neither rs3212227 nor
rs6887695 reached genome-wide signiﬁcance (P= 4.42×
10−4 and 6.47× 10− 6, respectively). One missense SNP
rs3213119 was very signiﬁcant (P= 2.90× 10− 18), whereas
another missense SNP rs3213096 was not (P= 0.096). This
discordant result may be because our study used continuous
IL-12p40 levels instead of (psoriasis) disease status as its
outcome variable. In our study, one functional SNP
(rs3213119 within IL12B) was highly signiﬁcantly associated
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with IL-12p40 blood levels. This helps conﬁrm the reliability
of our GWAS ﬁndings.
In summary, we report a strong relationship between
common variants within EBF1 and IL12B and blood
IL-12p40 levels among both melanoma cases and control
individuals. These genetic variants together accounted for
18.7% of variation in the IL-12p40 level. The IL12B region
was preliminarily identiﬁed as a susceptibility locus for mela-
noma risk; interestingly, as our prior case–control analysis
demonstrated no association between blood levels of
IL-12p40 and the presence of melanoma (Fang et al., 2014),
any mechanism associating IL12B with melanoma risk may
not be directly through altered IL-12p40 expression. In
contrast, the aggregate evidence suggests that the identiﬁed
preliminary association of the transcriptional activator EBF1
with overall survival among melanoma patients with
advanced stage could be mediated through altered expression
of IL-12p40. In order to fully characterize the molecular
mechanisms underlying the role of IL-12 in melanoma, further
research will need to investigate systematically the functions
of various cytokines and cytokine subunits, including
IL-12p40, IL-23, IL-12p70, and others.
MATERIALS AND METHODS
Study population
The study is part of a hospital-based case–control study of cutaneous
melanoma (CM), for which non-Hispanic white patients and controls
were recruited at MD Anderson between March 1998 and March
2011, including a total of 1,804 CM patients and 1,026 cancer-free
controls (friends or acquaintances accompanying patients to other
clinics). All individuals provided written, informed consent under an
institutional review board–approved protocol. Details of sample
collection have been previously described (Amos et al., 2011; Fang
et al., 2013). Melanoma patients with all stages of disease evaluated
in the Melanoma and Skin Cancer Center at the University of
Texas M.D. Anderson Cancer Center were eligible for inclusion.
Demographic data, pigmentation characteristics and sun exposure, and
clinical prognostic factors (2009 American Joint Committee on
Cancer stage, Breslow tumor thickness, ulceration and mitosis) were
collected. The AJCC stage at diagnosis was determined by direct
physical examination and pathologic review, supplemented by
laboratory and radiographic examinations. Length of follow-up and
survival duration was determined from the date of diagnosis to the
last contact date (date of last clinic note reviewed) or death. Patients
were deﬁned as having recurrence if they had a subsequent record of
regional, local, in-transit, or distant metastasis during follow-up.
Experiments
An Illumina Omni1-Quad_v1-0_B array was used to genotype
1,016,423 probes in 3,115 participants. After application of quality
control criteria (Supplementary Materials online, Supplementary
Tables S8 and S9 online), data from 818,237 SNPs remained
for 1,804 melanoma patients and 1,026 cancer-free controls
(Supplementary Figure S1 online). MACH was used to infer the
ungenotyped SNPs in the analysis according to HapMap reference
data with a denser set of markers (Li et al., 2009; Conway et al.,
2010). After imputation, we had 2.65 million SNPs available for
investigation.
Adequate plasma samples for IL-12p40 measurement were avail-
able from 573 cases (discovery) and 249 cases (case validation) from
the 1,804 patients (Supplementary Figure S1 online) (Fang et al.,
2014). Patient blood samples were drawn prior to receiving treat-
ment. In order to further validate the relationship between genetic
variants and IL-12p40 levels, following initial analysis of our discovery
and validation patient data sets, we evaluated IL-12p40 levels in 299
controls (Supplementary Figure S1 online). Samples were collected
into heparinized tubes and subjected to centrifugation at 1500 rpm
×10minutes. The plasma layer was stored at −80 °C before analysis;
IL12-p40 levels were determined from batch-thawed samples.
IL-12p40 levels were determined by an enzyme-linked immunosor-
bent assay (Invitrogen, Carlsbad, CA) using the sandwich technique
with an antibody that recognizes the IL-12p40 subunit either in the
form of free monomer or as part of a dimer. All measurements were
performed according to the procedures recommended by the manu-
facturer. The minimum detectable level of IL-12p40 was o2 pg/ml,
and the upper limit of linearity was 4500 pg/ml.
Statistical analysis
ProbABEL software was used for the initial genome-wide analysis
(Aulchenko et al., 2010), which comprised linear regression analysis
for log-transformed IL-12p40 onto genotype probabilities. The
additive effect for the reference allele of each SNP on IL-12p40
level was examined via the likelihood ratio test under the null
hypothesis of χ2 distribution with one degree of freedom. We also
included the ﬁrst three principal components to adjust for population
structure. We selected regions with multiple SNPs with a P-value
o10− 5 for validation using the validation case and control groups.
The threshold for genome-wide signiﬁcance was set at a standard
GWAS level of 5.0×10− 8 in order to reduce the risk of false
discovery (Altshuler et al., 2008). We validated GWAS results
obtained in our discovery data set in two validation data sets (one
case validation data set and one control validation data set). A
signiﬁcance level of 5.0× 10−8 in the discovery data set will have a
power of 93.4%; for the validation data sets, sample sizes of 249 and
299 with a signiﬁcance level 0.01 will have powers of 95.4 and
98.3%, respectively. Ten SNPs from our GWAS were then chosen for
evaluation for association with melanoma risk and outcome
measures, including eight block-representative SNPs and two
missense mutation SNPs in this region. We performed a logistic
regression analysis in 1,804 cases and 1,026 controls to observe the
relationship of these SNPs with melanoma susceptibility and built a
Cox regression analysis of 1,804 cases to investigate their association
with melanoma outcome through ProbABEL. We used the Bonferroni
correction to adjust for P-values in the univariate analysis (0.05-
/10= 0.005) and also used 0.05 for further multivariable analysis for
each SNP that was signiﬁcant in univariate analysis.
In addition to evaluating each SNP individually, we also performed
a gene-based test by combining χ2 statistics for all SNPs within
± 50 kb of the 5′ and 3′ untranslated regions of each gene (Liu et al.,
2010). This approach was used to further conﬁrm the signiﬁcant
region identiﬁed by the single variant test and additionally to seek
discovery of potential novel genes affecting IL-12p40 levels.
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